The medical and nonmedical use of opioids in the United States has increased significantly during the last decade.
1-4 Opioid use disorder (OUD) during pregnancy increased from 1.5 per 1000 live births to 6.5 per 1000 live births between 1999 and 2014.
5 Antenatal exposure to opioids has led to a 5-fold rise in the incidence of neonatal abstinence syndrome (NAS) between 2004 and 2014, a number that continues to increase.
6,7 Neonatal abstinence syndrome is a withdrawal syndrome that occurs after the interruption of the passive transfer of maternal opioids at the time of birth. The diagnosis of NAS is dependent on the presence of key signs of withdrawal, with severity being highly variable.
8,9 Every neonate exposed to opioids in utero is somewhere along the continuum of withdrawal. While some neonates have mild signs and normal physiologic functions, others have more severe NAS that requires pharmacologic treatment to avoid major complications.
10 Differences in the expression of NAS is associated with many factors, including the type(s) of opioid exposure, coexposure with other illicit drugs and/or psychotropic medications, genetic and epigenetic variability, the gestational age and sex of the neonate, breastfeeding, and parental engagement.
11-17